Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05823116 · ClinicalTrials.gov registry record · Phase 4
Continuous vs. Intermittent Infusion Vancomycin
A Phase 4 study, sponsored by Aaron Cook.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT05823116 is a Phase 4 study that has completed, run by Aaron Cook. The registered enrollment target is 37 participants.
The verdict
NCT05823116, a Phase 4 study, has completed, sponsored by Aaron Cook.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.
Interventions
- DRUG Vancomycin Continuous Infusion
- DRUG Vancomycin Intermittent Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2023-05-22 |
| Est. Completion | 2025-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05823116
The ClinicalTrials.gov registry entry for NCT05823116 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aaron Cook, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin Continuous Infusion is the first listed.
NCT05823116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05823116 about?
NCT05823116 is a clinical study titled "Continuous vs. Intermittent Infusion Vancomycin". Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.
What is the current status of trial NCT05823116?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2023-05-22. Estimated completion is 2025-06-15.
What interventions are being tested in trial NCT05823116?
The interventions under investigation include: Vancomycin Continuous Infusion (DRUG), Vancomycin Intermittent Infusion (DRUG).
Who is sponsoring clinical trial NCT05823116?
This trial is sponsored by Aaron Cook, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.